Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | APP | P05067 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14862510 | 0.79 | SLC6A4 (0.35) | KMT2ASLC6A4SLC6A2SLC6A3APP | |
| SCHEMBL14862509 | 0.79 | SLC6A4 (0.35) | KMT2ASLC6A4SLC6A2SLC6A3APP | |
| SCHEMBL17361821 | 0.77 | CARM1 (0.40) | — | |
| SCHEMBL11936060 | 0.75 | HRH3 (0.44) | KMT2AAPPMAPT | |
| SCHEMBL23536184 | 0.75 | NPC1 (0.40) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6783976 | 0.74 | PARP10 (0.49) | — | |
| SCHEMBL13104997 | 0.74 | KAT2B (0.44) | APP | |
| SCHEMBL13439276 | 0.73 | KDM4E (0.37) | KMT2AMAPT | |
| SCHEMBL11935533 | 0.73 | KDM4E (0.37) | KMT2AMAPT | |
| SCHEMBL13105792 | 0.73 | ALDH1A1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267945-A1 | AMINE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267945-A1 | AMINE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | KMT2A 2517/4885SLC6A4 328/4885SLC6A2 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.